Use of a probe to repeat sequence of the Y chromosome for detection of host cells in peripheral blood of bone marrow transplant recipients.
Use of a probe to repeat sequence of the Y chromosome for detection of host cells in peripheral blood of bone marrow transplant recipients.
复制标题
使用探针重复 Y 染色体序列来检测骨髓移植受者外周血中的宿主细胞。
DOI：
10.1093/ajcp/95.2.201
复制
发表时间：
1991
影响因子：
3.5
通讯作者：
Fisher,L
中科院分区：
文献类型：
--
作者：
Przepiorka,D;Thomas,ED;Durnam,DM;Fisher,L
原位杂交的Y染色体（Y-ISH）被用来确定残留的宿主细胞在外周血中的51个受体的性别不匹配的异基因骨髓不耗尽的T细胞后，条件与大剂量环磷酰胺和全身照射（TBI）。1例排斥移植物的患者在短暂的供体骨髓移植后表现出宿主细胞的快速重现。在其余50名患者中的49名中检测到低水平的宿主细胞。宿主外周血单个核细胞（PBMC）随时间下降，并在移植后4周内达到1.0 ± 0.2%的平台期，而宿主粒细胞（GRAN）的百分比则达到背景水平的平台期。宿主PBMC或GRAN的平均绝对数量小于0.015 × 109/L，并且在研究期间没有显著变化。无论是宿主PBMC或GRAN的百分比还是绝对数量都没有受到HLA匹配、TBI剂量强度、移植前缓解状态、移植后急性或慢性移植物抗宿主病或复发的后续发展的显著影响。作者得出结论，在异基因骨髓移植受者的外周血中发现少量残留宿主细胞是常见的，这些细胞的存在没有临床意义。
In situhybridization for the Y chromosome (Y-ISH) was used to identify residual host cells in the peripheral blood of 51 recipients of sex-mismatched allogeneic marrow not depleted of T cells following conditioning with high-dose cyclophosphamide and total body irradiation (TBI). One patient who rejected the graft showed rapid reappearance of host cells after transient donor marrow engraftment. Host cells were detected at low levels in 49 of the remaining 50 patients. Host peripheral blood mononuclear cells (PBMC) decreased with time and reached a plateau at 1.0 ± 0.2% within four weeks after transplantation, while the percentage of host granulocytes (GRAN) reached a plateau at background level. The mean absolute numbers of host PBMC or GRAN were less than 0.015 × 109/L and did not vary significantly over the period studied. Neither the percentages nor the absolute numbers of host PBMC or GRAN were significantly affected by HLA-matching, TBI dose-intensity, pretransplant remission status, subsequent development of acute or chronic graft-versus-host disease or relapse after transplantation. The authors conclude that it is common to find a few residual host cells in the peripheral blood of allogeneic marrow transplant recipients, and the presence of these cells has no clinical significance.